Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB339-031
- Development stage
- Preclinical
- Lead developer
- Twist Bioscience
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
TB339-031 is an investigational **VHH single-domain antibody** developed by Twist Bioscience for the treatment and prevention of COVID-19. It is a **nanobody-based biologic** directed against **SARS-CoV-2**, designed to bind and neutralize viral spike protein variants; public descriptions indicate it has a structure and potency similar to TB202-3 and showed activity against the **Delta** and **Epsilon** variants. As of October 2021, the program was reported to be in **late-stage discovery and validation testing**, with no identified brand name, approved formulation, or publicly disclosed clinical-stage development.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on TB339-031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB339-031.